Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
- Author:
Eun Jeong GONG
1
;
Ji Yong AHN
;
Hwoon Yong JUNG
;
Hyungchul PARK
;
Young Bo KO
;
Hee Kyong NA
;
Kee Wook JUNG
;
Do Hoon KIM
;
Jeong Hoon LEE
;
Kee Don CHOI
;
Ho June SONG
;
Gin Hyug LEE
;
Jin Ho KIM
Author Information
- Publication Type:Original Article
- Keywords: Helicobacter pylori; Mucosa-associated lymphoid tissue lymphoma; Remission
- MeSH: Helicobacter pylori*; Helicobacter*; Humans; Lymphoid Tissue; Lymphoma; Lymphoma, B-Cell, Marginal Zone*; Medical Records; Retrospective Studies
- From:Gut and Liver 2016;10(5):706-713
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage. METHODS: From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records. RESULTS: Of the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori-positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response. CONCLUSIONS: Eradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.
